[Click eStock] Genome and Company, Expectations for Microbiome Cultivation

[Asia Economy Reporter Junho Hwang] Hyundai Motor Securities analyzed on the 12th that Genome & Company is a company with cultivation technology encompassing both aerobic and anaerobic microbiomes, and has a high potential to expand its microbiome pipeline based on the GNOCLE platform through genomic analysis technology.

Genome & Company is a specialized company in immune oncology and microbiome CDMO. First, it is advancing the development of the microbiome pipeline with GEN-001 (a PD-L1 targeted immune oncology drug currently in Phase 1 clinical trials in the US in combination with Bavencio) and SB-121 (a microbiome that stimulates the secretion of oxytocin for autism treatment, currently in Phase 1 clinical trials in the US).

In the antibody pipeline, it is also developing GENA-104 (an anti-CNTN-4 antibody that can overcome or be combined with the low response rate of PD-1, targeting new biomarkers). In animal experiments, GENA-104 has shown a higher response rate than PD-1 and effects across various tumor types.

Researcher Minyong Eom of Hyundai Motor Securities stated, "It is a company with cultivation technology encompassing both aerobic and anaerobic microbiomes, and has a high potential to expand its microbiome pipeline based on the GNOCLE platform through genomic analysis technology," adding, "I recommend it as a stock of interest next year."

This content was produced with the assistance of AI translation services.